PHAR
Pharming Group N.V.
NASDAQ · Healthcare · Biotechnology · NL
$11.23
−2.01%Year over year
Reported trailing growth
- Revenue
- +7.8%
- EBITDA
- +49.3%
- EBIT
- -3.3%
- EPS
- +216.9%
- Free cash flow
- +4.2%
- Operating cash flow
- +3.2%
Forward estimates
Based on analyst estimates
- Revenue
- +7.8%
- EBITDA
- -3.5%
- EPS
- +54.2%
Three-year CAGR
- Revenue
- +22.3%
- EBITDA
- +1.2%
- EBIT
- +28.4%
- Net income
- -40.7%
- EPS
- -38.3%
- Free cash flow
- +38.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026